Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study to Evaluate the Long-term Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Genentech, Inc. Identifier:
First received: October 12, 2011
Last updated: February 4, 2015
Last verified: February 2015
This study is an open-label extension (OLE) trial to evaluate the safety and tolerability of rhuMAb Beta7 in patients with moderate to severe ulcerative colitis (UC) who were enrolled in the Phase II Study ABS4986g and meet the eligibility criteria for entry in the OLE study.

Condition Intervention Phase
Ulcerative Colitis
Drug: rhuMAb Beta7
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of Rhumab Beta7 in Patients With Moderate to Severe Ulcerative Colitis

Resource links provided by NLM:

Further study details as provided by Genentech, Inc.:

Primary Outcome Measures:
  • Incidence of adverse events [ Time Frame: up to 104 weeks ] [ Designated as safety issue: No ]
  • Incidence of serious adverse events [ Time Frame: up to 104 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Clinically significant changes in vital signs and safety laboratory measures [ Time Frame: up to 104 weeks ] [ Designated as safety issue: No ]
  • Study discontinuation due to adverse events [ Time Frame: up to 104 weeks ] [ Designated as safety issue: No ]
  • Incidence and nature of injection-site reactions and hypersensitivity [ Time Frame: up to 104 weeks ] [ Designated as safety issue: No ]
  • Incidence of infectious complications [ Time Frame: up to 104 weeks ] [ Designated as safety issue: No ]
  • Immunogenicity as measured by the incidence of anti-therapeutic antibodies (ATAs) [ Time Frame: up to 104 weeks ] [ Designated as safety issue: No ]
  • Clinical signs and symptoms of allergic reaction to rhuMAb Beta7 [ Time Frame: up to 104 weeks ] [ Designated as safety issue: No ]

Enrollment: 116
Study Start Date: November 2011
Estimated Study Completion Date: February 2015
Estimated Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: rhuMAb Beta7
Repeating subcutaneous injection


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

All patients (placebo or active) who were previously enrolled in the Phase II study (ABS4986g) and fulfill any of the following criteria:

  • Patients who have not obtained a clinical response in the Phase II study (ABS4986g) by Week 10 (the end of the Phase II treatment phase) may enter this OLE trial at any time after Week 10 and up to and including Week 28
  • Patients who have a clinical response in the Phase II study (ABS4986g) at Week 10 but have had a flare of UC between Week 10 and Week 28
  • Ability and willingness to provide written informed consent and comply with the requirements of the OLE protocol
  • Males and females with reproductive potential must be willing to use a highly effective method of contraception, vaginal ring, intrauterine device, physical barrier, or vasectomized partner) from study start to a minimum of 4 months (approximately 5 half lives)

Patients at study sites in the United States must meet the following additional inclusion requirements for OLE study entry:

  • Concomitant immunosuppressive therapy must be discontinued before entry into this OLE study
  • Patients must have tapered completely off oral corticosteroids within 24 weeks of enrollment to this OLE study

Exclusion Criteria:

  • Patients who did not complete through Week 10 of the Phase II study (ABS4986g)
  • Pregnancy or lactation
  • Any new malignancy within the past 6 months
  • Any new (since enrolling in the Phase II study [ABS4986g]), significant, uncontrolled co- morbidity, such as neurological, cardiac, pulmonary, renal, hepatic, endocrine, or GI disorders
  • Any new clinically significant signs or symptoms of infection as judged by the investigator
  • Any abnormal lab values recorded at the last visit completed in the Phase II study (ABS4986g)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01461317

  Show 41 Study Locations
Sponsors and Collaborators
Genentech, Inc.
Study Director: Clinical Trials Genentech, Inc.
  More Information

Responsible Party: Genentech, Inc. Identifier: NCT01461317     History of Changes
Other Study ID Numbers: GA27927 
Study First Received: October 12, 2011
Last Updated: February 4, 2015
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Colitis, Ulcerative
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases processed this record on October 21, 2016